Our data showed that the risk of death and recurrence conferred by SSBP1 rs6976500 CG/GG genotypes were more prominent in GC patients without receiving FOLFOX-based ACT than those with ACT, suggesting the presence of potential interaction between SNP rs6976500 and ACT for modulating GC prognosis. The gene discussed is SSBP1; the disease is gastric cancer.